On July 22, DexCom fell 5.06% in regular trading, trading at $70.91 USD/share, with Turnover of $147 million.
Within the Health Care Equipment sector where DexCom belongs, the overall sector performance was weak. Among individual stocks, Intuitive Surgical down 2.45%, Abbott Laboratories up 0.49%, Stryker down 1.37%, Boston Scientific down 0.94%, Edwards Lifesciences down 0.6%.
DexCom is a medical device company focused on the design, development, and commercialization of continuous glucose monitoring systems. The company is scheduled to release its Q2 earnings on July 30, with an expected EPS of $0.61.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)